Conestoga Capital Advisors LLC Acquires 11,105 Shares of Omnicell, Inc. (OMCL)
Conestoga Capital Advisors LLC increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 0.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,617,706 shares of the company’s stock after buying an additional 11,105 shares during the quarter. Omnicell accounts for approximately 3.7% of Conestoga Capital Advisors LLC’s holdings, making the stock its largest holding. Conestoga Capital Advisors LLC owned 4.32% of Omnicell worth $82,584,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Oppenheimer Asset Management Inc. acquired a new stake in Omnicell during the 1st quarter worth $170,000. Turner Investments LLC acquired a new stake in Omnicell during the 2nd quarter worth $181,000. Riverhead Capital Management LLC raised its stake in Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after buying an additional 1,830 shares during the period. Flinton Capital Management LLC raised its stake in Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after buying an additional 1,802 shares during the period. Finally, Sei Investments Co. raised its stake in Omnicell by 36.4% during the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after buying an additional 1,242 shares during the period.
In related news, VP Peter J. Kuipers sold 3,532 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $50.96, for a total value of $179,990.72. Following the sale, the vice president now owns 40,714 shares in the company, valued at approximately $2,074,785.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jorge R. Taborga sold 20,719 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $50.98, for a total transaction of $1,056,254.62. Following the completion of the sale, the vice president now owns 53,270 shares in the company, valued at approximately $2,715,704.60. The disclosure for this sale can be found here. Insiders sold a total of 106,594 shares of company stock worth $5,379,391 in the last 90 days. 3.77% of the stock is currently owned by company insiders.
Several research firms have issued reports on OMCL. Zacks Investment Research downgraded Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday. Craig Hallum reissued a “buy” rating and issued a $62.00 price target (up previously from $52.00) on shares of Omnicell in a research note on Monday. Cantor Fitzgerald reissued a “buy” rating and issued a $47.00 price target on shares of Omnicell in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $55.00 price target on shares of Omnicell in a research note on Thursday, October 19th. Finally, Dougherty & Co lifted their price target on Omnicell from $45.00 to $49.00 and gave the company a “buy” rating in a research note on Friday, July 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $54.86.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/01/conestoga-capital-advisors-llc-acquires-11105-shares-of-omnicell-inc-omcl.html.
Omnicell, Inc. (NASDAQ OMCL) traded down 2.7110% during mid-day trading on Wednesday, hitting $48.4499. The company’s stock had a trading volume of 49,358 shares. The firm has a 50 day moving average of $50.97 and a 200-day moving average of $46.16. Omnicell, Inc. has a 52-week low of $30.35 and a 52-week high of $55.40. The firm’s market cap is $1.81 billion.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The company had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. During the same quarter in the prior year, the business posted $0.40 EPS. The firm’s revenue was up 5.7% compared to the same quarter last year. On average, equities research analysts expect that Omnicell, Inc. will post $1.30 EPS for the current fiscal year.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.